Replacing animal testing

Korean LunchReplacing animal testing is good for business

Photo caption: Let’s put it all on one table (OpenTox Asia 2017, South Korea)

Every day, we come into contact with chemicals whose effects on the human body and the environment have not been adequately tested. Over 100,000 of them need urgent evaluation – and that’s something traditional animal-based methods can’t cope with. In addition to the humane and ethical reasons long raised by animal activists, the need for safety testing has become too vast, the numbers too large, the expense involved too great. Most importantly, the findings based on animal testing are often inconclusive for humans. A lab mouse’s physiology is not the same as a human baby’s.

From 20-24 August, researchers from around the world will gather in Seattle at the 10th World Congress on Alternatives and Animal Use in the Life Sciences to discuss how to move science away from animal testing. For animal rights groups, of course, this move is overdue. But, now, the chemical, pharmaceutical and cosmetic industries – long-pilloried as adversaries by activists - are themselves convinced that animal testing is no longer the appropriate model.

WC10 brings together people from all over the world, across disciplines and industries, who are working to develop new in vitro and in silico methods to replace animal testing, as well as on frameworks for these methods’ integration, validation, industrial use and regulatory acceptance.

You could call this combined effort the Human Safety Project, because the challenge is even bigger than the Human Genome Project.

My own experience with establishing the international non-profit OpenTox Association and the related OpenRiskNet infrastructure development has shown that, with a common language, standards, data and methods, scientists everywhere can reliably work together. When you get it right, it is like a Korean banquet: 50 different dishes on the table and everyone sharing the experience and making comments. Which test is more reliable? What are your results? How do we come to a consensus? How do we validate?

If we can achieve this kind of interaction and discussion, the emerging science of safety assessment will save time and resources.

With over 100,000 chemicals to evaluate, there is certainly no time to waste.

 

Dr Barry Hardy is a Managing Director (CEO) at Douglas Connect

 

About Edelweiss Connect

Edelweiss Connect has developed computer software that helps combine data from many different sources and formats into a useable form for evaluation and re-use. In addition, we have developed other software programs that can use the collected data and data from in vitro tests to predict the safety of chemical compounds in the human body.

Tags

Latest Tweets

Edelweiss Connect (7 hours ago)
Making AI available to companies, large and small - CEO Tom Bell explains why @Vertexlabs_ is a founding member of… https://t.co/oj7y7jNqq0
Edelweiss Connect (6 days ago)
#SaferWorldbyDesign is a new solution-oriented, safety assessment framework to support the design of intelligent, s… https://t.co/Rv6BsS7HHb
Edelweiss Connect (1 week ago)
The typical modern laboratory is crammed with electronic equipment of various ages and complexity, all using differ… https://t.co/5yVtReZd7U
Edelweiss Connect (1 week ago)
EdelweissData™ in the Lab = reproducible, reliable, harmonised data organisation, processing, visualisation, and re… https://t.co/7xfD6PvqXp
Edelweiss Connect (2 weeks ago)
RT @barryhardy: We look forward to attending #EuroTox2019 in Helsinki. Let us know if you'll be there! You can find @EdelweissConn at boo…

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland
  • Phone: +41 61 633 29 78
  • Email: info@edelweissconnect.com

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA
  • Phone: +1 252 654 9003
  • Email: info@edelweissconnect.com